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Abstract
The Janus kinase 2 mutant V617F occurs with high frequency in myeloproliferative neoplasms. Further mutations affecting the Janus kinase
family have been discovered mostly in leukaemias and in myeloproliferative neoplasms. Owing to their involvement in neoplasia, inflammatory
diseases and in the immune response, Janus kinases are promising targets for kinase inhibitor therapy in these disease settings. Various quan-
titative assays including two newly developed screening assays were used to characterize the function of different small-molecule compounds
in cells expressing Jak2V617F. A detailed comparative analysis of different Janus kinase inhibitors in our quantitative assays and the subse-
quent characterization of additional activities demonstrated for the first time that the most potent Jak2 inhibitor in our study, CEP701, also tar-
gets Aurora kinases. CEP701 shows a unique combination of both activities which is not found in other compounds also targeting Jak2.
Furthermore, colony forming cell assays showed that Janus kinase 2 inhibitors preferentially suppressed the growth of erythroid colonies,
whereas inhibitors of Aurora kinases preferentially blocked myeloid colony growth. CEP701 demonstrated a combined suppression of both col-
ony types. Moreover, we show that combined application of a Janus and an Aurora kinase inhibitor recapitulated the effect observed for
CEP701 but might allow for more flexibility in combining both activities in clinical settings, e.g. in the treatment of myeloproliferative neoplasms.
The newly developed screening assays are high throughput compatible and allow an easy detection of new compounds with Janus kinase 2
inhibitory activity.
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Introduction
In 2005, a somatic activating point mutation in Janus kinase 2 (Jak2)
—Jak2V617F was discovered in Philadelphia chromosome-negative
myeloproliferative neoplasm (MPN) patients [1–5]. Almost every
patient suffering from polycythemia vera (PV) carries this mutation
and it is found in about 50% of essential thrombocythemia (ET) and
primary myelofibrosis (PMF) patients. These haematopoietic disor-
ders are characterized by an overproduction of mature-appearing
blood cells of one or more lineages and can lead to failure of the bone
marrow and ineffective haematopoiesis [6]. Further genetic altera-
tions affecting all members of the Janus kinase family (Jak1, Jak2,
Jak3 and Tyk2) have been discovered in leukaemias and other can-
cers since 2005 [7]. Many of these mutations have been shown to
constitutively activate the Jaks, resulting in cytokine hypersensitivity
and constitutive activation of signal transducers and activators of
transcription (STAT) 3 and 5, mitogen-activated protein (MAP) kinas-
es and the phosphoinositide-3-kinase/protein kinase B (PI3K/AKT)
pathway [2, 8–13]. As Janus kinases play a critical role in the patho-
genesis of MPN and different other cancers (e.g. leukaemias, multiple
myeloma) but also in inflammatory disorders (e.g. rheumatoid arthri-
tis, psoriasis) and in the setting of allograft transplant rejection, the
interest in developing small-molecule inhibitors of the Jak family has
concomitantly risen. In the last few years new and potent inhibitors of
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Janus kinases (mostly ATP-competitive compounds) have been
developed for different clinical applications (reviewed in [7, 14, 15]).
A number of compounds have entered clinical trials [16, 17] and
INCB018424, a Jak1 and Jak2 targeting compound, was recently
approved by the FDA and the European Commission for treatment of
myelofibrosis. However, the survival rate of myelofibrosis patients
treated with INCB018424 is not different from patients treated with
standard therapy [18, 19] and it is still ambiguous if the Jak2V617F
allele burden is effectively improved upon Jak2 inhibitor treatment.
Thus, the discovery of new compounds with Jak2 inhibitory activity
as well as the development of alternative treatment strategies is
highly required.
Here, we developed two new intact cell fluorescent screening pro-
cedures, which allow a reproducible monitoring of Jak2 activity,
based on a comparative investigation of several described Jak(2)
inhibitors in the cellular context. Some of the compounds did not inhi-
bit Jak2V617F, and also the Jak-targeting inhibitors showed different
potencies in intact cell assays. Furthermore, we show for the first
time that the potent Jak inhibitor CEP701, which is tested in clinical
trials, inhibits also Aurora kinases. CEP701 shows a unique combina-
tion of both activities, which is not found in other Aurora kinase inhib-
itors also targeting Janus kinases (e.g. AT9283). Moreover, we show
that a combined application of Jak2 inhibitors with Aurora kinase
inhibitors recapitulates the effects observed for CEP701 and might be




All compounds were dissolved in DMSO at a concentration of 10 mM.
For the experiments the stock solutions of the inhibitors were diluted in
the respective cell culture media. From Symansis (Auckland, New
Zealand) we purchased JNJ7706621, TG101209, TG101348 and VX680.
From Synkinase (San Diego, CA, USA) we acquired CYT387 and VX680.
Calbiochem (Merck4Biosciences, Darmstadt, Germany) provided AG490,
JAK Inhibitor 1 (JI1, pyridone 6, CMP6) and WP1066. Selleck Chemi-
cals (Houston, TX, USA) provided AT9283 and VX680. CEP701 was
from Tocris Bioscience (Bristol, UK). LFM-A13 was purchased from
Axxora (San Diego, CA, USA), Sunitinib was from Cayman Chemical
Company (Ann Arbor, MI, USA) and TG101348 was also provided by
Axon Medchem (Groningen, The Netherlands).
Cell culture
The HEL (human erythroleukaemia) cell line was purchased at Leibniz
Institute DSMZ (Braunschweig, Germany). The cells were amplified,
aliquots were frozen and after thawing the cells were cultivated for
2 months at most. The cells were maintained in RPMI–1640 medium
(Lonza, Basel, Switzerland) supplemented with 10% FBS, 100 mg/l
streptomycin, 60 mg/l penicillin and 2 mM L-glutamine. For details on
the cultivation of the other cell lines see the Supporting Information.
Cell lysis and Western blot analysis
All steps of cell lysis were performed on ice. HEL cells were either lysed
with Mammalian Protein Extraction Reagent (M-PER, Thermo Fisher
Scientific, Waltham, MA, USA), which was supplemented with 49 Lae-
mmli buffer or directly in 19 Laemmli buffer. After denaturation, the
samples were run on SDS polyacrylamide gels, transferred to a PVDF
(Carl Roth, Karlsruhe, Germany) or nitrocellulose membrane (GE Health-
care, Little Chalfont, UK) and probed with the respective antibodies. The
anti-phospho-histone H3, anti-histone H3, anti-phospho-Jak2, anti-Jak2
and anti-phospho-STAT3 antibodies were purchased from Cell Signalling
Technology (Danvers, MA, USA). The anti-phospho-Jak1, anti-Jak3,
anti-STAT5 and anti-tubulin antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The anti-phospho-STAT5 and
anti-STAT3 antibodies were purchased from BD Biosciences (Franklin
Lakes, NJ, USA), whereas the anti-GFP antibody (used to detect STAT3-
YFP) was from Rockland Immunochemicals (Gilbertsville, PA, USA).
The anti-phospho-Jak1 antibody was used to detect phosphorylated
Jak3 as described previously [20]. This is possible because the anti-
body is cross-reactive and Jak1 (130 kD) and Jak3 (110 kD) are well
separated by SDS polyacrylamide gel electrophoresis. The horseradish
peroxidase-conjugated secondary antibodies were purchased from Cell
Signalling Technology. Luminescent signals were detected using an ECL
solution as described before [21]. Secondary antibodies IRDye® 700
and 800, used for the fluorescent Western blot detection with the
Odyssey® Infrared Imaging System (LI-COR Biosciences, Lincoln, NE,
USA), were obtained from LI-COR Biosciences. Quantitation was per-
formed with the analysis software V3.0 provided by LI-COR Biosciences.
IC50 values were determined using GraphPad Prism 5.01, log [inhibitor]
versus response-Variable slope 4PL curve fit from biological replicates
(n = 4–12).
Cell proliferation assay
Human erythroleukaemia cells were cultured with inhibitor at indicated
concentrations or left untreated for 72 hrs. Cells were washed and
resuspended in FACS buffer (PBS, 5% FBS, 0.1% NaN3) containing
15,000 phycoerythrin-labelled CalibriteTM Beads per ml (BD Biosciences)
and 1 lM SYTOX® Blue Dead Cell Stain (Invitrogen, Life Technologies,
Carlsbad, CA, USA) and incubated for 5 min. on ice. Samples were run
on a FACSCanto II flow cytometer (BD Biosciences) and analysed using
FACSDiva (BD Biosciences) software. The amount of inhibitor-treated
cells was calculated as percentage of maximum number of cells
(= untreated control). IC50 values were determined using GraphPad
Prism 5.01, log [inhibitor] versus response-Variable slope 4PL curve fit
from biological replicates (n = 3–5).
pSTAT-ZsGreen reporter gene assay
HEK-FRT-TO-HAEpoR-Jak2V617F cells stably integrating the pSTAT-
ZsGreen plasmid, henceforth called “HEK-V617F-STAT-Rep.” cells, were
treated with 10 ng/ml doxycycline to induce expression of Jak2V617F
for 24 hrs and were additionally treated with 7500, 2500, 833, 277.8,
92.6, 30.8, 10.3, 3.4 or 1.1 nM of the different inhibitors. The cells were
harvested using trypsin-EDTA, washed and resuspended in FACS buffer
and analysed on a FACSCanto II flow cytometer. The fluorescence signal
of the sample containing 1.1 nM of inhibitor was set to 100%. IC50
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values were determined using GraphPad Prism 5.01, log [inhibitor]
versus response-Variable slope 4PL curve fit from biological replicate
experiments (n = 4).
STAT3-YFP translocation assay
c2A-FRT-TI-Jak2V617F/STAT3-YFP cells were seeded on 96-well glass
bottom plates (Matrical Bioscience, Spokane, WA, USA) and induced
with 5 lg/ml doxycycline. Different concentrations of inhibitors (2, 6,
18, 54, 162, 486, 1458 nM) were added after 24 hrs of doxycycline
treatment for another 12–24 hrs. After staining the cells with the DNA
dye Hoechst 33342 (Invitrogen, Life Technologies) at a concentration of
1 lg/ml for 20 min., the cells were washed with PBS and fixed using
4% paraformaldehyde (PFA). Finally, PBS was added to each well and
automated confocal cell imaging of the cells on 96-well plates was per-
formed using a LSM 510 inverted laser scanning microscope (Carl Zeiss
AG, Oberkochen, Germany). YFP was detected with kexc = 514 nm and
kem = 530–600 nm, the Hoechst 33342-stained nuclei were recorded
with kexc = 405 nm and kem = 420–490 nm. Quantitation of YFP
signals was performed using the cell image analysis software “Cell Pro-
filer” (www.cellprofiler.org) [22, 23]. Briefly, the nuclei shape was deter-
mined automatically and the amount of YFP fluorescence that
colocalized with the Hoechst 33342-stained nuclei was determined. The
nuclear YFP signal intensities were normalized with respect to overall
YFP signal intensities to account for differences in STAT3-YFP expres-
sion that can occur. IC50 values were determined using GraphPad Prism
5.01, log [inhibitor] versus response-Variable slope 4PL curve fit from
biological replicate experiments (n = 3–8) performed each time in tech-
nical quadruplicates.
Cell cycle analysis
Human erythroleukaemia cells were cultivated with inhibitor at indicated
concentrations or left untreated for 24 and 48 hrs. Cells were washed
once with PBS and fixed in 70% ethanol over night at 4°C. Fixed cells
were washed with PBS and then resuspended in PBS containing 50 lg/
ml propidium iodide and 50 lg/ml RNase and incubated at 37°C for
15 min. Cell cycle profiles were recorded on a FACSCanto II flow
cytometer.
Colony forming cell assay
All experiments on patient samples were approved by the Comite
National d’Etique de Recherche (CNER) in Luxembourg according to the
Declaration of Helsinki. An informed, written consent of every patient
included in the study has been obtained.
Peripheral blood mononuclear cells (PBMC) from Jak2V617F-positive
MPN patients were isolated by a Ficoll-Paque PLUS (GE Healthcare)
gradient centrifugation according to the manufacturer’s instructions.
CD34+ cells were purified using the CD34 MicroBead Kit on LS columns
and a QuadroMACS Separator (all from Miltenyi Biotec, Bergisch Glad-
bach, Germany) according to the manufacturer’s protocol. The CD34+
cells (500 cells per 35 mm dish) were seeded in methylcellulose med-
ium MethoCult® H4230 (StemCell Technologies, Grenoble, France) sup-
plemented with 1 U/ml Epo (Calbiochem, Merck4Biosciences), 10 ng/ml
IL-3, 10 ng/ml G-CSF and 10 ng/ml GM-CSF (all from PeproTech,
Rocky Hill, NJ, USA) according to the manufacturer’s instructions. Cells
were incubated with inhibitors at indicated concentrations or left
untreated. The different colony types (CFU-E, BFU-E and CFU-GM) were
counted using an inverted microscope after 12–16 days of culture. The
amount of colonies grown from inhibitor-treated cells was calculated as
percentage of maximum number of colonies (= untreated control). Rep-
licates with cells isolated from three patients were performed.
Results
Some of the proposed Jak inhibitors do not
target Jak2 but suppress cell growth
We chose 12 compounds (AT9283, CEP701, TG101209, TG101348,
CYT387, JI1, VX680, Sunitinib, WP1066, AG490, LFM-A13 and
JNJ7706621, see Figure S1) with proposed Jak2 inhibitory activity
and/or reported growth inhibitory activity towards cells from MPN
patients for comparative testing using different read-outs and cell
systems.
Human erythroleukaemia cells endogenously expressing the con-
stitutively active mutant Jak2V617F were used to assess the effect of
the compounds on proliferation (Fig. 1A). Furthermore, the actual
capacity of the different compounds to inhibit Jaks was evaluated by
monitoring phosphorylation of STAT5, a direct target of Jak2V617F
which is constitutively phosphorylated in HEL cells (Fig. 1B and
Figure S2C). Several compounds such as AT9283, CEP701,
TG101209 and JI1 reduced proliferation of HEL cells very effectively
and at the same time strongly reduced phosphorylation of STAT5 at a
concentration of 0.5 lM. TG101348 and CYT387 showed the same
effects but were less efficient. Six of the 12 compounds (VX680, Suni-
tinib, WP1066, AG490, LFM-A13 and JNJ7706621) did not inhibit the
phosphorylation of STAT5 up to concentrations of 5 lM (Fig. 1B and
Figure S2C). AG490, LFM-A13 and JNJ7706621 neither affected cell
growth at concentrations up to 1 lM (data not shown). However,
Sunitinib and WP1066 had a moderate effect on HEL cell growth, while
VX680 very efficiently inhibited HEL cell growth already at 0.3 lM.
The effects of these compounds were validated in other cellular
systems including the UKE-1 (endogenously expressing Jak2V617F
[24]) and BA/F3-EpoR-Jak2V617F [10] cell lines (Figure S2A and B).
The phosphorylation of STAT5 was efficiently decreased upon treat-
ment with JI1, TG101209, TG101348, AT98283, CEP701 and
CYT387, whereas Sunitinib, VX680, WP1066 and AG490 did not inhi-
bit STAT5 phosphorylation. Furthermore, two potent Jak2 inhibitors
(TG101209, CEP701) and VX680 inhibited very efficiently the cell pro-
liferation of UKE-1 and BA/F3-EpoR-Jak2V617F cells.
The Jak2 phosphorylation status is increased
upon Jak inhibition in HEL cells
Treatment with compounds targeting Jak2V617F (AT9283, CEP701,
TG101209, TG101348, CYT387 and JI1) led to an increased phos-
phorylation of Jak2 (Fig. 1B), although the Jak2V617F-mediated
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phosphorylation of STAT5 was prevented by the inhibitor treatment.
The intensity of the hyper-phosphorylation and the inhibitor concen-
tration, at which it occurs, are reproducible for each inhibitor. More-
over, the effect of hyper-phosphorylation upon Jak inhibitor treatment
was not restricted to Jak2V617F in HEL cells. In HEK-EpoR cells
doxycycline-inducibly expressing the Jak2V617F or Jak2K539L [8]
mutant an increase in Jak-mutant phosphorylation was observed
upon treatment with JI1 (Figure S2D). Hyper-phosphorylation of
Jak2V617F in HEL cells was also observed after treatment with
CP690,550 (another pan-Jak inhibitor, Figure S2E). Moreover, in
CMK cells expressing the constitutively active Jak3 mutant A572V (a
cell line which was not further characterized in this study) hyper-
phosphorylation of Jak3A572V was also observed after CP690,550
treatment (Figure S2F). Interestingly, the increase in Jak2 and Jak3
phosphorylation in the aforementioned cellular systems was not
observed for the compounds, which did not inhibit the phosphoryla-
tion of STAT5 (VX680, Sunitinib, WP1066, AG490, LFM-A13 and
JNJ7706621; Fig. 1B and Figure S2C and F). Taken together, the
Jak2 phosphorylation state upon inhibitor treatment does not neces-
sarily reflect the Jak2 activation status and is thus not a suitable
parameter to monitor the efficacy of a Jak-targeting ATP-competitive
compound.
Jak2V617F activity or inhibition can be
effectively monitored by two new assays using
fluorescent read-outs of STAT activation
Investigating the efficacy of inhibitors using Western blot detection is
not applicable for high throughput analysis. Therefore, we developed
intact cell assays, which are easy to handle and high throughput com-
patible to monitor Jak2 activity: we here describe the first Jak2V617F-
controlled STAT-reporter gene assay using the fluorescent read-out
protein ZsGreen. In addition, we measured STAT3-YFP translocation
to monitor Jak2V617F activity in a confocal microscopy assay. As
both assays utilize fluorescent proteins, complex treatments are not
required prior to the measurements.
The HEK-V617F-STAT-Rep. cells harbour a stably integrated
ZsGreen reporter gene construct which contains 12 STAT consensus
sequences in its promoter region (see Fig. 2A and Supporting Infor-
mation). Jak2V617F is induced upon doxycycline treatment of the
cells leading to phosphorylation of STAT5 and STAT3 (Figure S3A)
[8], which in turn results in the expression of the fluorescent ZsGreen
protein (Figure S3B and C). Jak inhibitor treatment prevented STAT
phosphorylation (Figure S3A) which in turn resulted in decreased
expression of the fluorescent protein, which was monitored by flow
cytometry (Fig. 2B and Figure S3D) or alternatively using a fluorime-
ter (data not shown).
The c2A-FRT-TI-Jak2V617F/STAT3-YFP cells, doxycycline-induc-
ibly expressing STAT3-YFP and Jak2V617F (Figure S4A and B),
were used in the confocal imaging assay. Jak2V617F phosphory-
lates STAT3-YFP which then translocates into the nucleus (Fig. 2C).
Jak inhibitor treatment led to decreased levels of STAT3-YFP
phosphorylation (Figure S4C) which in turn resulted in decreased
translocation of STAT3-YFP into the nucleus (Fig. 2C). The phos-
phorylation-dependent STAT3-YFP nuclear translocation was quanti-
tated upon inhibitor treatment using the ‘Cell Profiler’ software (see
Figure S4D). Nuclear localization of STAT3-YFP was suppressed,
when Jak2V617F was inhibited by JI1, TG101209, TG101348,
AT9283, CEP701 and CYT387 (Fig. 2C and D; Figure S4D and E and
A
B
Fig. 1 Effect of the different inhibitors on proliferation of HEL cells and Jak2V617F signal transduction. (A) HEL cells were treated with different
compounds at concentrations of 0.3 or 1 lM or left untreated for 72 hrs. One representative biological replicate is shown. (B) HEL cells were trea-
ted with 0.5, 1 or 5 lM of the different inhibitors or left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and
Jak2 (P-Jak2) was assessed by Western blot immunodetection.
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Table 1) but was not observed for compounds not targeting
Jak2V617F.
In vitro kinase assay data lack accuracy in
predicting inhibitor behaviour in intact cells
Comparison of the in vitro kinase assay data of JI1, TG101209,
TG101348, CEP701, CYT387 and AT9283 with the IC50 values derived
from Western blot analysis of phospho-STAT5 signals in HEL cells
revealed discrepancies in the behaviour of the compounds in these
two assays (Table 1, Figure S5A). As expected, higher concentrations
of the compounds were needed in the cellular assays to compete with
the intracellular ATP concentrations (1–5 mM). Besides this, the five
compounds showing IC50 values between 0.76 and 1.5 nM (JI1,
TG101209, CYT387, AT9283 and CEP701) in the in vitro kinase assay
showed a considerably larger range of IC50 values in the cellular
assays. CYT387 had significantly higher IC50 values in all intact cell
assays compared with JI1, both being equipotent in the in vitro kinase
assay. On the other hand, TG101348 and CYT387 have roughly the
same activity in intact cell assays, while CYT387 was approximately
one order of magnitude more potent in the in vitro kinase assay. As a
conclusion, the exact activity of a compound in cells is hard to predict
from its activity in the in vitro kinase assay, showing the need to
combine both technologies to clearly uncover the activity of a certain
compound on its respective target kinases. A comparison of our
in vitro kinase data with those previously published is shown in
Figure S5B.
A detailed comparative study of a selection of
compounds
We further investigated a selection of compounds and compared the
IC50 values determined from two reference assays (Western blot
analysis of phospho-STAT5 and proliferation assays in Jak2V617F-
dependently growing HEL cells) with the IC50 values obtained in the
new fluorescent assays (Table 1). The efficacy of JI1, TG101209,
TG101348 and CYT387 within the assays was always comparable. In
general, the concentrations to achieve half-maximal inhibition are
Fig. 2 Two newly developed fluorescent intact cell screening assays
allow detecting differences in efficiency between the various Jak inhibi-
tors. (A) Schematic representation of the STAT-responsive reporter gene
construct. (B) HEK-V617F-STAT-Rep. cells were treated with 7500,
2500, 833, 278, 93, 31, 10.3, 3.4 or 1.1 nM of the different inhibitors
for 24 hrs. The fluorescent reporter gene product was measured by
flow cytometry. Overlays of the curves derived from three independent
biological triplicates for the indicated inhibitors are shown. (C) c2A-
FRT-TI-Jak2V617F/STAT3-YFP cells were treated with 2 or 1458 nM of
TG101209 for 12 hrs. Upper panels: The nuclear localization of phos-
phorylated STAT3-YFP and Hoechst 33342-stained nuclei are shown for
a concentration of 2 nM of TG101209, when Jak2V617F is not inhibited.
Lower panels: The predominant cytoplasmic localization of non-phos-
phorylated STAT3-YFP is shown for a concentration of 1458 nM of
TG101209, when Jak2V617F is inhibited. The nuclear staining by
Hoechst 33342 remains unchanged. (D) c2A-FRT-TI-Jak2V617F/STAT3-
YFP cells were treated with 2, 6, 18, 54, 162, 486 or 1458 nM of the
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slightly higher in the fluorescent reporter gene assay than those in
the confocal imaging assay or Western blot analysis. This variation
between assays may reflect differences in Jak2V617F expression in
the different cell systems. For the Jak inhibitors JI1, TG101209,
TG101348 and CYT387, we show that the IC50 values for growth inhi-
bition are generally higher than those determined from Western blot
experiments tracing STAT5 phosphorylation (Table 1). As seen in
Figure 1 and in Table 1 again, discrepancies between IC50 values
determined by phospho-STAT5 measurements (Western blot analy-
sis) or growth inhibition can reveal inhibitors, which have a different
mode of action than the inhibition of Jak2 (e.g. VX680). Interestingly,
also the Jak inhibitors AT9283 and CEP701 showed differences when
comparing the IC50 values of Western blot analysis, our new assays
and proliferation assays (Table 1). For these two compounds the IC50
values in our novel assays and the growth assay were lower than
expected from the Western blot experiments. This at first glance sur-
prising behaviour sparked a more detailed investigation of these
effects as described below.
CEP701 has Aurora kinase-inhibitory potential
Based on the confocal images of the STAT3-YFP translocation assay
the software ‘Cell Profiler’ allows the analysis of many parameters in
parallel. Taking advantage of this we found that treatment with
AT9283, VX680 and CEP701 led to an increase in nuclei size (Fig. 3A
and Figure S6A) at 6, 18 and 162 nM respectively, while TG101209
did not show this effect. When treating cell lines not expressing
Jak2V617F (2C4, HCT-116 and K-562 cells) with VX680 and CEP701,
this effect was also clearly visible (Figure S6B). This indicates that
the increase in nuclear size is independent of Jak2V617F.
As AT9283 and VX680 are known to inhibit Aurora kinases [25,
26], we analysed these two compounds and CEP701 using cell cycle
analysis. A typical effect of Aurora kinase inhibition is the emergence
of an 8n peak in addition to the 2n (G1 phase) and 4n (G2/M phase)
peaks normally observed in growing cell cultures [27]. Jak inhibitors
(TG101209 in Fig. 3B and Figure S6C) are known to inhibit growth of
HEL cells by inducing G1 arrest [28], reflected by the reduction in the
G2/M peak intensity (dark grey bars in Fig. 3B). AT9283, VX680 and
CEP701, however, all showed the emergence of an 8n peak (black
bars in Fig. 3B) and an increase in the 4n/2n ratio (compare light and
dark grey bars in Fig. 3B, Figure S6C). AT9283 was the most efficient
compound followed by VX680 and CEP701 in all related assays. HEL
cells also increased in size with rising time of treatment owing to Aur-
ora kinase inhibition by AT9283, VX680 and CEP701, whereas the
effect was not observed for TG101209 (Figure S6D). Moreover, we
investigated the effect of the compounds on phosphorylation of his-
tone H3, a direct target of Aurora kinase B [29]. Reduction in histone













JI1 1.6 133  62 291  40 197  73 506  18
TG101209 0.76 92  18 156  10 125  45 243  41
TG101348 11 636  203 850  101 385  61 725  85
CYT387 1.5 633  90 794  7 459  126 1180  413
AT9283 0.88 309  126 105  15 74  38 29  5
CEP701 1.2 97  39 111  22 45  15 81  20
VX680 480 No inhibition No inhibition No inhibition 158  26
WP1066 – No inhibition No inhibition – n.d.§
Sunitinib 2400 No inhibition – – n.d.§
JNJ7706621 – No inhibition – – n.d.§
AG490 – No inhibition – – –
LFM-A13 – No inhibition – – –
*The IC50 values (mean  SD) determined from biological replicates in the different assays are shown.
†The Jak2 in vitro kinase assays were performed by Caliper Discovery Alliances & Services. Exact assay conditions are described in the Sup-
porting Information.
‡Phospho-STAT5 (P-STAT5) levels in HEL cells were assessed by Western blot immunodetection.
§IC50 values were not determined as these compounds did not show sufficient growth reduction in the tested concentration range.
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H3 phosphorylation could be demonstrated for all three inhibitors,
AT9283 again being the most efficient one followed by VX680 and
CEP701. TG101209 had only very little effect (Fig. 3C). The decline of
histone H3 phosphorylation upon treatment with VX680 or CEP701
could also be detected in UKE-1 and BA/F3-EpoR-Jak2V617F cells
(Figure S6E). In vitro kinase assays showed that CEP701 indeed
inhibited Aurora kinase A and B with similar IC50 values as AT9283
and VX680 (Figure S6F).
Jak inhibitors preferentially suppress growth of
erythroid colonies, whereas Aurora kinase
inhibitors preferentially block myeloid colony
growth
We analysed the effect of several compounds in colony forming cell
(CFC) assays. For this, the development of erythroid and myeloid
colonies originating from haematopoietic progenitor cells (CD34+)
derived from Jak2V617F-positive MPN patients was monitored. Jak
inhibitors without additional Aurora kinase activity reduced erythroid
and myeloid colony growth dose dependently, generally being more
efficient in affecting erythroid colony numbers (Fig. 4A). Interest-
ingly, AT9283 (Aurora kinase and Jak inhibitor) and VX680 (Aurora
kinase inhibitor) reduced the numbers of myeloid colonies very effi-
ciently but had less effect on erythroid colonies (Fig. 4). The same
behaviour was also observed for other Aurora kinase inhibitors
(AZD1152, Danusertib and SNS314, Figure S7). AT9283 was the
most potent Aurora kinase inhibitor in our test, but VX680 was also
very efficient: hardly any colony could be detected at concentrations
of 50 or 300 nM. Among the Jak inhibitors with Aurora kinase-
inhibitory potential, CEP701 showed an intermediate behaviour com-
pared with the Jak or Aurora kinase inhibitors. Interestingly, the ery-
throid and myeloid colonies were equally well suppressed at a given
concentration. The differential effects of Jak and Aurora kinase
inhibitors on growth of myeloid colonies were also observed when
CD34+ cells of healthy donors were subjected to CFC assays (data
not shown).
Jak and Aurora kinase inhibitors cooperate to
suppress growth of Jak2V617F-expressing cells
As Jak inhibitors rather suppressed growth of erythroid colonies,
whereas Aurora kinase inhibitors preferentially blocked myeloid col-
ony growth, we applied combinations of Jak and Aurora kinase inhibi-
tors in the CFC assay. We observed that, also when applied in
combination, the two types of inhibitors conserved their function:
myeloid colony growth is preferentially suppressed dose dependently
by VX680 and erythroid colony growth is preferentially suppressed




Fig. 3 CEP701 has Aurora kinase-inhibitory activity (A) c2A-FRT-TI-
Jak2V617F/STAT3-YFP cells were treated with the indicated inhibitors
for 24 hrs. The cells were analysed by confocal imaging. The increase
in nuclear size as determined with the software ‘Cell Profiler’ is shown
for CEP701, AT9283 and VX680 from one representative biological repli-
cate. TG101209 is shown as negative control. (B) HEL cells were trea-
ted with 500 nM CEP701, VX680, TG101209 or 100 nM AT9283 for
24 hrs and then subjected to cell cycle analysis. The relative proportion
(in %) of cells constituting the subG1 = apoptotic (white bars),
G1 = 2n (light grey bars), G2/M = 4n (dark grey bars) or 8n (black
bars) peaks are shown. The mean  SD from three biological replicates
is shown. (C) HEL cells were treated with 100 ng/ml of Nocodazole for
16 hrs to block the cells in the M phase of cell cycle and afterwards
incubated with different concentrations (0.25, 0.5 or 1 lM) of CEP701,
VX680, AT9283 and TG101209 or left untreated for 3 hrs. Relative
phospho-histone H3 levels were assessed by quantitative Western blot
immunodetection.
ª 2012 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. 271
J. Cell. Mol. Med. Vol 17, No 2, 2013
Furthermore, a drug combination analysis of VX680 and TG101209
according to the Chou-Talalay method (see Supporting Information) in
BA/F3-EpoR-Jak2V617F cells was performed (Figure S9). The CI val-
ues range from 0.654 to 0.835 for a total dose of inhibitors of 0.55 to
1.27 lM indicating slight to moderate synergistic effects for this com-
bination treatment. Only for the lowest concentration of compounds
when the inhibitory effect on cell proliferation is less pronounced a CI
value of 0.996 indicates an additive effect for the drug combination. We
also find synergism when treating UKE-1 cells with VX680 and
TG101209 in combination (data not shown).
Discussion
In this comparative study of several proposed Janus kinase inhibitors,
our aim was to characterize the compounds in depth in the cellular
context, mainly concerning their activity towards Jak2. We also aimed
at identifying reproducibly measurable parameters, which could be
used to establish robust intact cell assays to monitor Jak2 activity.
Phosphorylation of Jak2 was not suitable to monitor the activation
state of Jak2V617F upon inhibitor treatment as we observed that
hyper-phosphorylation of Jak2 occurs upon treatment with any inhibi-
tor targeting Jak2, although the inhibitors efficiently prevented STAT5
phosphorylation (Fig. 1B and Figure S2E; [8, 30]). The effect was
also observed with Jak2K539L and Jak3A572V (Figure S2D and F)
and has been described in analogue-sensitive mutants of Jak1 and
Jak3 [20]. This ‘phosphorylation priming’ [31, 32] might result from a
stabilization of the active conformation of the two Jaks in the cyto-
kine/cytokine-receptor/Jak signalling complex. The Jaks might be able
to trans-phosphorylate each other when the inhibitor is, at times, dis-
placed competitively by ATP. However, the fast inhibitor displacement
of ATP does not allow efficient signal transduction so that negative
feedback mechanisms like recruitment of phosphatases or SOCS pro-
tein expression [8] are prevented. JI1 and CP690,550 are known to
bind the kinase domains of Jak1, Jak2, Jak3 and Tyk2 in the active
conformation (type I kinase inhibitors) [33–35]. The observed hyper-
phosphorylation of Jak2V617F upon inhibitor treatment also suggests
that in addition to JI1 and CP690,550, TG101209, TG101348,
AT9283, CEP701 and CYT387 also bind the Jak2 kinase domain in the
A
B
Fig. 5 Jak and Aurora kinase inhibitors cooperate to suppress growth of
Jak2V617F-expressing cells. CD34+ cells of Jak2V617F-positive MPN
patients were subjected to CFC assays using the Aurora kinase inhibitor
VX680 and the Jak2 inhibitor TG101209 in combination. The results of
one experiment are shown. The replicates were performed with cells
isolated from three different patients.
Fig. 4 Aurora kinase and Jak2 inhibition has differential effects on
cells of the erythroid and myeloid lineage in CFC assays. CD34+
cells of Jak2V617F-positive MPN patients were subjected to CFC
assays in the absence or presence of kinase inhibitors at different
concentrations. The amount of erythroid colonies (black bars) or
myeloid colonies (white bars) grown from inhibitor-treated cells
was calculated as percentage of maximum number of colonies in
the untreated control. The results of one experiment are shown.
The replicates were performed with cells isolated from three dif-
ferent patients.
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active conformation. It has been shown very recently that type II
inhibitors binding the Jak2 kinase domain in the inactive conforma-
tion do not induce an increased Jak2 phosphorylation [36]. Consider-
ing the different Jak phosphorylation behaviour upon binding of a
type I or II kinase inhibitor and the recently reported fact that Jaks do
not necessarily need to be phosphorylated to be active and phosphor-
ylate their substrates [20, 37], we conclude that Jak phosphorylation
is not the ideal parameter to investigate Jak activity.
Jak2V617F has been described to activate multiple STAT factors
(STAT5, STAT3 and STAT1) by phosphorylation in HEL cells and in
other model cell lines [2, 8, 12, 38]. The activation of STAT proteins
can be monitored by multiple methods. To set up and validate our
new screening assays we used the quantitation of STAT5 phosphor-
ylation by Western blot as reference, as it is a robust way to moni-
tor Jak2V617F activity [8]. Here, we describe two new, easy to
handle, quick and high throughput compatible intact cell assays to
monitor Jak2 activity: (a) a STAT-dependent reporter gene assay, in
which Jak2V617F-driven STAT activation leads to expression of the
fluorescent ZsGreen reporter and (b) a confocal imaging assay, in
which nuclear localization of STAT3-YFP dependent on Jak2V617F
activity is monitored. In our comparative study we tested 12 com-
pounds in different assay formats to determine their inhibitory activ-
ity towards Jak2V617F and/or to possibly uncover different
mechanisms of action, which might ultimately be useful in treat-
ment of MPN. Intriguingly, a first assessment of the compounds
using Western blot quantitation of phospho-STAT5 showed that 6
of 12 compounds were not able to inhibit Jak2V617F-mediated sig-
nal transduction at nanomolar to low micromolar concentrations.
For many drugs low micromolar concentrations can be achieved in
patients and interestingly, the low micromolar concentration range
is also the limit, for which kinase inhibitors can be assumed to be
reasonably specific [39]. JI1, TG101209, TG101348, CYT387,
AT9283 and CEP701 all efficiently inhibited Jak2V617F-induced
STAT5 phosphorylation with IC50 values in the nanomolar concen-
tration range. TG101348 and CYT387 were, however, clearly less
active than the other Jak-targeting compounds. All Jak inhibitors
also dose dependently suppressed cell growth in HEL cells and in
CFC assays with CD34+ cells obtained from Jak2V617F-positive
MPN patients. None of the remaining compounds (VX680, Sunitinib,
WP1066, AG490, LFM-A13 and JNJ7706621) prevented phosphory-
lation of STAT5 (up to a concentration of 5 lM) and thus none
inhibits Jak2V617F in intact cells under these conditions. The failure
of AG490 to inhibit Jak (in a different cellular context) was reported
by our group before [40]. Interestingly, among the compounds
without Jak inhibitory potential, VX680 very efficiently suppressed
HEL cell growth, while Sunitinib and WP1066 only had moderate
effects. This suggests that combination of VX680 with a Jak inhibi-
tor might have beneficial effects on growth suppression of
Jak2V617F-positive cells.
During the analysis of the different inhibitors we compared data
from the in vitro kinase assays to data obtained in the quantitative
cellular assays (quantitative Western blot analysis of STAT5 phos-
phorylation, reporter gene assay, STAT3-YFP translocation assay).
Interestingly, there are more significant differences between the activ-
ities of the compounds AT9283, CEP701, JI1, TG101209, TG101348
and CYT387 in intact cells than expected from comparing their behav-
iour in the in vitro kinase assays. These differences may be caused by
a number of parameters [39, 41]. However, potent compounds in
in vitro kinase assays in general also show good cellular activity [39,
41]. Therefore, both technologies should be combined to clearly
uncover the activity of a certain compound on its respective target
kinases. Unfortunately, it is not possible to extrapolate the exact cellu-
lar activity from in vitro kinase assay data [39, 42]; this is recapitu-
lated by our comparative analysis (Table 1). (A similar effect is seen
when comparing Aurora kinase assays with the corresponding cellu-
lar assays). However, active and non-active compounds can be
clearly distinguished in the in vitro kinase assays. Compounds which
did not inhibit Jak2 in in vitro kinase assays at single or double digit
nanomolar concentrations were inactive in cellular assays (e.g.
VX680 and Sunitinib). Comparison of our and published in vitro
kinase assay data (Figure S5B) show that the IC50 values do not cor-
respond very well, the greatest divergence of greater than 10-fold is
observed for CYT387, which might be owing to differing assay condi-
tions. However, all the efficient Jak2 inhibitors (AT9283, CEP701, JI1,
TG101209, TG101348 and CYT387) show low nanomolar activity in
our hands and in the published studies.
Another advantage of the cellular assays was the revelation of
quantitative and qualitative differences between the Jak-targeting
compounds. Interestingly, quantitative evaluation of the phospho-
STAT5 Western blot data revealed that TG101209 and CEP701 were
most efficiently inhibiting Jak2V617F activity in HEL cells, with IC50
values around 100 nM, CEP701 thereby being the most efficient com-
pound among those tested in clinical trials [43]. In our hands,
AT9283 [25] was of intermediate potency (IC50 around 300 nM) com-
pared with CEP701 and the compounds with less efficacy as
TG101348 [44] and CYT387 [45] (IC50 values  600 nM in HEL
cells). A more thorough comparison of the IC50 values derived from
the different cellular assays (Table 1) revealed that the relative effi-
ciency of JI1, TG101209, TG101348 and CYT387 was always compa-
rable within one assay and that the IC50 values for growth inhibition
are generally higher than those determined from Western blot experi-
ments tracing STAT5 phosphorylation. However, AT9283 and CEP701
were more efficiently suppressing growth than it would have been
expected from comparison with the other Jak-targeting compounds.
Such discrepancies can be indicative of a different mode of action of
these compounds, as is the case for VX680, which shows no inhibi-
tion of Jak2V617F in all assays but suppresses HEL cell growth very
efficiently (IC50 = 158 nM). The confocal imaging assay revealed an
increase in nuclei size after treatment with VX680, AT9283 or CEP701
(Fig. 3A and Figure S6A), whereas JI1, TG101209, TG101348 and
CYT387 did not have this effect. The known Aurora kinase inhibitors
AT9283 and VX680 [25, 26] showed this effect even below 50 nM,
whereas CEP701 increased nuclei size starting at a concentration of
162 nM. CEP701 was, to our knowledge, not reported before to inhi-
bit Aurora kinases in cellular assays, although it was reported to bind
Aurora kinases in an in vitro kinase binding assay (KINOMEscan)
[46]. We confirmed Aurora kinase inhibition by CEP701 using various
assays (Fig. 3 and Figure S6). CEP701 and AT9283 show different
potencies against Jak2V617F and Aurora kinases. AT9283 seems to
inhibit Aurora kinases at very low concentrations (nuclei size
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increases at concentrations ranging from 6 to 18 nM, in Fig. 3A and
Figure S6A), while it inhibits Jak2V617F with an IC50 of 309 nM. In
contrast, CEP701 is a more potent inhibitor of Jak2V617F
(IC50 = 97 nM), while Aurora kinase inhibition is efficient only at
concentrations from 162 to 486 nM (nuclei size increase in Fig. 3A
and Figure S6A). Thus, an advantage of CEP701 might be the fact
that it targets the disease-specific Jak2V617F protein more efficiently
than it inhibits Aurora kinases. This might lead to fewer side
effects than compounds whose main target is not Jak2V617F (e.g.
AT9283).
When testing the compounds in the CFC assay with haematopoiet-
ic progenitor cells (CD34+) derived from Jak2V617F-positive MPN
patients, we found that in general Jak inhibitors preferentially
suppressed growth of erythroid colonies, whereas Aurora kinase
inhibitors (AT9283, VX680, AZD1152, Danusertib and SNS314) pref-
erentially blocked myeloid colony growth (Fig. 4 and Figure S7).
AT9283 was so efficient in suppressing colony growth at very low
concentrations, that it is questionable whether Jak2V617F inhibition
plays any role in this effect at all. Interestingly, CEP701 showed an
intermediate behaviour compared with the Jak or the Aurora kinase
inhibitors. Myeloid colony suppression was equal or slightly better
compared with erythroid colony suppression at a given concentration
of CEP701. As MPN patients also have significant numbers of myeloid
inflammatory cells, the Aurora kinase-inhibitory potential of CEP701
might turn out to be especially interesting in suppressing the disease-
associated inflammation [47]. The effect of CEP701 (Jak and Aurora
kinase inhibition) can be imitated using two inhibitors, one with pre-
dominant Jak inhibitory activity (TG101209) and one with predomi-
nant Aurora kinase-inhibitory activity (VX680). Indeed, combination
of VX680 and TG101209 (Fig. 5) decreased the number of erythroid
and myeloid colonies in parallel reflecting the beneficial effects of
both inhibitors. Interestingly, we could demonstrate a synergistic
effect of the combined treatment with VX680 and TG101209 in cell
lines expressing Jak2V617F emphasizing that the combination of a
Jak and an Aurora kinase inhibitor is more efficient in suppressing cell
proliferation than the respective single treatment. We conclude
that Jak2V617F and Aurora kinase inhibition if correctly modulated
(as in CEP701) is an attractive concept to target erythroid growth and
the myeloid cell-governed inflammation occurring in MPN. An alterna-
tive approach might be to combine two compounds for the treatment
as long as the side effects caused by the compounds remain
tolerable.
Clinical trials involving the Aurora kinase inhibitors AT9283 and
VX680 for the treatment of MPN or myeloid leukaemia have been
terminated (www.clinicaltrials.gov). However, other Aurora kinase
inhibitors (AZD1152 and Danusertib) are tested in clinical trials for
application in acute myeloid leukaemia or relapsed chronic myeloid
leukaemia and might prove to be well tolerable. Interesting Jak inhibi-
tors to test in conjunction with Aurora kinase inhibitors are those
which have entered clinical trials for MPN or other haematologic
malignancies (TG101348, LY2784544, CYT387, SB1518) [15] and
INCB018424, which has been approved for treatment of myelofibrosis
by the FDA and the European Commission. Jak inhibitors in clinical
trials for rheumatoid arthritis or other autoimmune disorders [Tofacit-
inib (CP690,550), LY3009104, GLPG0634, VX509 or AC430] [15]
might also be used in conjunction with low dose Aurora kinase inhibi-
tors to control inflammation.
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Materials and methods 
 
Cell culture 
The Jak2V617F-positive UKE-1 cell line was a gift from Dr. Walter Fiedler (University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany). The cells were cultured in Iscove’s modified 
Dulbecco’s medium (IMDM, Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 
10% FBS, 100 mg/l streptomycin, 60 mg/l penicillin, 10 ng/ml IL-3 and 10 ng/ml GM-CSF. The 
BA/F3-EpoR-Jak2V617F cells (a murine pro B cell line, stably expressing Jak2V617F and the 
Epo receptor) were a kind gift from Dr. Thomas Fischer (Otto-von-Guericke-University, 
Magdeburg, Germany). They were maintained in RPMI-1640 medium (Lonza, Basel, 
Switzerland) supplemented with 10% FBS, 100 mg/l streptomycin, 60 mg/l penicillin, 2 mM L-
glutamine, 2 μg/ml puromycin and 1 mg/ml G418.   
The CMK (acute megakaryocytic leukaemia cells expressing Jak3A572V) and K-562 (chronic 
myeloid leukaemia cells positive for Bcr-Abl) cell lines were cultured in RPMI-1640 medium 
supplemented with 10% FBS, 100 mg/l streptomycin, 60 mg/l penicillin and 2 mM L-glutamine. 
The colon carcinoma cell line HCT-116 and the fibrosarcoma cell line 2C4 were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM, Lonza) supplemented with 10% FBS, 100 mg/l 
streptomycin, 60 mg/l penicillin and 25 mM HEPES. 
 
Generation of cDNA constructs 
Standard cloning procedures were followed throughout. The integrity of all constructs was 
verified by DNA sequencing at GATC Biotech (Konstanz, Germany). Restriction enzymes were 
from New England Biolabs (Ipswich, MA, USA). 
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pSTAT-ZsGreen was generated as follows: pZsGreen1-DR was purchased from Clontech 
Laboratories (Mountain View, CA, USA). A new multiple cloning site with PacI, AgeI, NheI, 
EcoRI, AscI restriction sites and a TATA box were introduced by opening the vector with XhoI 
and SmaI and inserting the annealed oligonucleotides 5’-TCGAGAGCTTAATTAAAGCACCG 
GTAAAGCTAGCTAGAATTCGAAGGCGCGCCTATATAACTGGTACCACAGGGCCC-3’ 
and 5‘-GGGCCCTGTGGTACCAGTTATATAGGCGCGCCTTCGAATTCTTAGCTAGCTTT 
ACCGGTGCTTTAATTAAGCTC-3’. 12 STAT binding sites were then introduced in two steps. 
First, the annealed oligonucleotides 5’-CCGGTTTCCGGGAAAGCGTTTCCGGGAAAGCGTT 
TCCGGGAAAGCGTTTCCGGGAAAGCTTTCCCGTAAAGCTTTCCCGTAAAG-3’ and     
5’-CTAGCTTTACGGGAAAGCTTTACGGGAAAGCTTTCCCGGAAACGCTTTCCCGGAA 
ACGCTTTCCCGGAAACGCTTTCCCGGAAA-3’ were inserted using AgeI and NheI. Then, 
the annealed oligonucleotides 5‘-CTAGCGGTTTCCGGGAAAGCGTTTCCGGGAAAGCGTT 
TCCGGGAAAGCGTTTCCGGGAAAGCTTTCCCGTAAAGCTTTCCCGTAAAG-3’ and     
5’-AATTCTTTACGGGAAAGCTTTACGGGAAAGCTTTCCCGGAAACGCTTTCCCGGAA 
ACGCTTTCCCGGAAACGCTTTCCCGGAAACCG-3’ were inserted using NheI and EcoRI 
yielding a reporter gene construct with 8 STAT5 consensus binding sites from the CIS promoter 
[1] and 4 STAT3/1 consensus binding sites of the mutated SIE sequence (m67SIE) [2-3] 
preceding the ZsGreen-coding region. 
The plasmid pBOF/V5-Jak2V617F/STAT3-YFP was built as follows: The generation of the 
inducible, bidirectional Flp-in vector pBOF was described before [4]. STAT3-YFP cDNA was 
sub-cloned into pBOF using SbfI and SwaI restriction sites. V5-Jak2V617F was then sub-cloned 
using AgeI and NheI. 
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pTET-onpuro was derived from the vector pTET-on (Clontech Laboratories) by replacing the 
neomycin resistance gene by a puromycin resistance gene, which was amplified by PCR and 
inserted into BglII and BstBI restriction sites. 
 
Generation of stable cell lines 
γ2A cells (a Jak2-deficient fibrosarcoma cell line) were a kind gift from I. M. Kerr. The cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Lonza) supplemented with 10% 
FBS, 100 mg/l streptomycin, 60 mg/l penicillin and 25 mM HEPES. The cells were transfected 
with Superfect (Qiagen, Hilden, Germany) or Lipofectamine 2000 (Invitrogen, Life 
Technologies, Carlsbad, CA, USA) according to protocol. γ2A cells were first transfected with 
the plasmid pFRT-lac-zeo (Invitrogen, Life Technologies) (FRT: FLP Recombination Target) 
and selected for stable integration using 100 µg/ml Zeocin (InvivoGen, San Diego, CA, USA) to 
generate γ2A-FRT cells. Clones were checked for the presence of the “Flp-in” site using the β-gal 
staining kit (Invitrogen, Life Technologies). The γ2A-FRT cells were then transfected with 
pTET-onpuro and selected for stable integration using 1 µg/ml puromycin (InvivoGen). Clones 
were tested for the presence of the reverse tetracycline-responsive transcriptional activator by 
PCR. The resulting γ2A-FRT-TI (TI: Tet-Inducible) cells were transfected with pBOF/V5-
Jak2V617F/STAT3-YFP and selected for stable integration using hygromycin (InvivoGen) to 
yield the resulting γ2A-FRT-TI-Jak2V617F/STAT3-YFP. Cells were controlled for the 
expression of STAT3-YFP by fluorescence microscopy after induction with 5 μg/ml doxycycline 
for 24 hrs.  
HEK293-FRT-TO-EpoR-Jak2V617F cells [5] were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Lonza) supplemented with 10% FBS, 100 mg/l streptomycin, 60 mg/l 
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penicillin and 25 mM HEPES. The cells were transfected with the pSTAT-ZsGreen reporter 
plasmid using TransIT-LT1 (Mirus Bio, Madison, WI, USA) and were selected for stable 
integration using 1 mg/ml G418 (InvivoGen). Clones were tested for expression of the ZsGreen 
protein by fluorescence microscopy after inducing Jak2V617F expression with 5 ng/ml 
doxycycline for 24 hrs.  
 
Quantification of STAT5 phosphorylation 
The quantification of the phospho-STAT5 signals was performed using the analysis software 
V3.0 provided by LI-COR Biosciences (Lincoln, NE, USA). The phospho-STAT5 signal was 
normalized with respect to the signal of total STAT5 (loading control) for each lane. Each 
normalized phospho-STAT5 signal was then divided by the mean of all normalized phospho-
STAT5 signals of one membrane to adjust for the possible variation of signal intensity between 
different membranes (each membrane includes one biological replicate). The signal intensity of 
phospho-STAT5 is represented as percentage of the strongest signal. 
 
CyQUANT® Cell Proliferation Assay  
The cells were cultured with inhibitor at indicated concentrations or left untreated for up to 
72 hrs. Afterwards, they were incubated with the freshly prepared detection reagent of the 
CyQUANT® Direct Cell Proliferation Assay Kit (Invitrogen, Life Technologies) according to the 
manufacturer’s instructions. The fluorescence signal was detected with λexc = 485 nm and λem = 
520 nm in a FLUOstar OPTIMA microplate reader (BMG LABTECH, Ortenberg, Germany). 
The amount of inhibitor-treated cells was calculated as percentage of maximum number of cells 
(= untreated control) from biological replicates (n = 3 - 5). 
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Analysis of drug combinations according to the Chou-Talalay method 
The growth inhibitory effect of two single drugs (VX680 and TG101209) and their combination 
was assessed by the CyQUANT® Direct Cell Proliferation Assay Kit (see above). The 
compounds were applied in various concentrations while keeping the concentration ratio between 
the two inhibitors constant (for details please see legend for Fig. S9). A dose-effect analysis of 
the drug combination was performed using the CompuSyn software [6-7] according to the Chou-
Talalay method [8]. The Combination Index (CI) value is then the quantitative measure of the 
dose-effect analysis of a drug combination, meaning CI < 1 represents synergism, CI > 1 
corresponds to antagonism and CI ≈ 1 represents an additive effect for the drug combination.  
 
In vitro kinase assays 
The Jak2, Aurora A and Aurora B kinase assays were performed by Caliper Discovery Alliances 
& Services “CDAS” using the LabChip technology from Caliper Life Sciences (Hopkinton, MA, 
USA) using standard conditions and Staurosporine as a reference compound. Ten half log 
dilutions of the different compounds were used. All assays were performed at KmATP for each 
kinase. Briefly, the Jak2 kinase assays were performed using 15 nM of enzyme, 1.5 μM of 
substrate and 14 μM of ATP in 100 mM HEPES, pH 8.0 supplemented with 0.004% Triton X-
100. The Aurora A kinase assays were performed using 4 nM of enzyme, 1.5 μM of substrate and 
25 μM of ATP in 100 mM HEPES, pH 7.5 supplemented with 0.1% Brij-35. The Aurora B 
kinase assays were performed using 5 nM of enzyme, 1.5 μM of substrate and 5 μM of ATP in 
100 mM HEPES, pH 7.5 supplemented with 0.1% Brij-35. The project was completed using the 
Caliper LabChip 3000 and a 12-sipper LabChip. IC50 values were determined using GraphPad 
Prism 5.01, log [inhibitor] vs. response-Variable slope 4PL curve fit from duplicate experiments. 
 5
Gäbler et al.                              Supporting Information 
Cell size determination 
HEL cells were cultivated with 600 nM of CEP701, TG101209, VX680 or 100 nM of AT9283 or 
left untreated for 24, 48 or 72 hrs. The average cell diameter (d) of HEL cells was determined 
with a CEDEX XS cell counter (Roche Diagnostics, Basel, Switzerland). The cell volume (V) 
was then calculated using the formula: (4/3) ⋅ π ⋅ (d/2).  
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A, Chemical structures of compounds, which have Jak inhibitory activity in living cells at 
concentrations below or around 1 μM. B, Structures of compounds, which had no potential to 
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Figure S2: Validation of effects of the investigated compounds in other relevant cell systems  
A, UKE-1 and BA/F3-EpoR-Jak2V617F cells were treated with different inhibitors at a 
concentration of 2.5 μM or left untreated for 3 hrs. The expression and phosphorylation state of 
STAT5 (P-STAT5) was assessed by Western blot immunodetection. B, UKE-1 and BA/F3-
EpoR-Jak2V617F cells were treated with TG101209, VX680 and CEP701 at concentrations of 
0.3 or 1 μM or left untreated for 72 hrs. Cell proliferation was assessed by the CyQUANT cell 
proliferation assay. C, HEL cells were treated with 0.5, 1 or 5 μM of the indicated inhibitors or 
left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and Jak2 
(P-Jak2) was assessed by Western blot immunodetection. D, HEK-EpoR cells stably and 
inducibly expressing Jak2V617F or Jak2K539L were treated with 1 ng/ml doxycycline (+) or left 
untreated (-) for 12 hrs. Subsequently, the cells were treated with 1 μM of JI1 for 3 hrs as 
indicated. Western blots were detected as described in C. E, HEL cells were treated with 0.5, 1 or 
5 μM of CP690,550 or left untreated for 3 hrs. Western blots were detected as described in C. F, 
CMK cells were treated with 0.5, 1 or 5 μM of the indicated inhibitors or left untreated for 3 hrs. 
The expression and phosphorylation state of STAT5 (P-STAT5) was assessed by Western blot 
immunodetection. To assess the phosphorylation state of Jak3 (P-Jak3) an anti-phospho-Jak1 
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Figure S3: Characterization of the HEK-V617F-STAT-Rep. cells 
A, HEK-V617F-STAT-Rep. cells were treated with 10 ng/ml doxycycline for 12 hrs. 
Subsequently, TG101209 (T), CEP701 (C), AT9283 (A) or VX680 (V) was added at a 
concentration of 2.5 μM for 3 hrs. The phosphorylation state of STAT5 (P-STAT5) and STAT3 
(P-STAT3) and the expression of STAT5, STAT3, Jak2 and tubulin was assessed by Western 
blot immunodetection. B, HEK-V617F-STAT-Rep. cells were treated with 10 ng/ml doxycycline 
(green line) or left untreated (black line) for 24 hrs and were then subjected to flow cytometric 
analysis. ZsGreen-positive cells were gated so that less than 1% of the untreated cells were 
considered ZsGreen-positive. In the histogram all events to the right of the dashed line are 
considered cells expressing ZsGreen. C, HEK-V617F-STAT-Rep. cells were treated with 10 
ng/ml doxycycline (right panel) or left untreated (left panel) for 24 hrs. Induction with 
doxycycline leads to green-fluorescent cells compared to untreated cells not showing any green 
fluorescence. D, Determination of the IC50 values of the different inhibitors in the reporter gene 
assay by flow cytometry: HEK-V617F-STAT-Rep. cells were induced with 10 ng/ml 
doxycycline and were additionally treated with 7500, 2500, 833, 278, 93, 31, 10.3, 3.4 or 1.1 nM 
of the different inhibitors for 24 hrs. IC50 values were determined using GraphPad Prism 5.01, log 
[inhibitor] vs. response-Variable slope 4PL curve fit from duplicate experiments. The graphs 
shows mean values ± standard deviation of three biological replicate experiments, from which the 
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Figure S4: Characterization of the γ2A-FRT-TI-Jak2V617F/STAT3-YFP cells 
A, γ2A-FRT-TI-Jak2V617F/STAT3-YFP cells were induced with 5 μg/ml doxycycline for 
different time points (as indicated). Quantitative Western blot detection was performed as 
described in Materials and Methods. The expression kinetics of STAT3-YFP and Jak2V617F 
upon doxycycline treatment was assessed by Western blot immunodetection with anti-GFP and 
anti-Jak2 antibodies, respectively. Phosphorylation of STAT3-YFP by Jak2V617F was detected 
with an anti-phospho-STAT3 antibody. Tubulin detection was used to show equal loading. B, 
Quantitation of triplicate experiments (similar to A) of Jak2V617F and STAT3-YFP expression 
is shown. After 24 hrs both proteins are robustly expressed. Therefore, this time point was chosen 
to perform the assay. C, γ2A-FRT-TI-Jak2V617F/STAT3-YFP cells were treated with 5 μg/ml 
doxycycline for 24 hrs. Subsequently, TG101209 (T), CEP701 (C), AT9283 (A) or VX680 (V) at 
a concentration of 2.5 μM was added for 3 hrs. The expression and phosphorylation state of 
STAT3-YFP (P-STAT3-YFP) and the expression of Jak2 and tubulin were assessed by Western 
blot immunodetection. D, After induction with doxycycline γ2A-FRT-TI-Jak2V617F/STAT3-
YFP cells were treated with 2 or 4374 nM of TG101209 for 12 hrs. The left panel shows the 
automatic recognition of the nuclei by the “Cell Profiler” software; nuclear borders are 
highlighted by a red line. The right panel shows the automatic recognition of the YFP signal by 
the software, also delineated by a red line. The nuclear borders are additionally depicted by a 
white line in these pictures. When Jak2V617F is not inhibited at low concentrations of 
TG101209 (2 nM), STAT3-YFP is located mostly in the nucleus. Upon inhibition of Jak2V617F 
(4374 nM TG101209) STAT3-YFP is localized rather in the cytoplasm. E, Determination of the 
IC50 values of the different inhibitors in the STAT3-YFP translocation assay: γ2A-FRT-TI-
Jak2V617F/STAT3-YFP were induced with 5 μg/ml doxycycline and were additionally treated 
with 7500, 2500, 833, 278, 93, 31, 10.3, 3.4 or 1.1 nM of the different inhibitors for 12 hrs. IC50 
values were determined using GraphPad Prism 5.01, log [inhibitor] vs. response-Variable slope 
4PL curve fit from duplicate experiments. The graphs show the curves from 4 technical replicates 





















































































































a IC50 value was determined with a competitive binding assay (KINOMEscan).
Compound Caliper (nM) Literature (nM) Reference
AT9283 0.88 1.2 [9]
CEP701 1.2 0.9 [10]
CYT387 1.5 18 [11]
JI1 (pyridone 6) 1.6 2.1 [4, 12-13]
TG101209 0.76 6 [14]
TG101348 11 3 [15]
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Figure S5: In vitro kinase data 
A, IC50 values for Jak2 inhibition were determined in an in vitro kinase assay for the indicated 
inhibitors. The assays were performed by Caliper Discovery Alliances & Services “CDAS” 
applying the LabChip technology from Caliper Life Sciences using standard conditions and 
Staurosporine as a reference compound. IC50 values were determined using GraphPad Prism 5.01, 
log [inhibitor] vs. response-Variable slope 4PL curve fit from duplicate experiments. B, The table 
shows IC50 values of in vitro Jak2 kinase assays determined by Caliper Life Sciences in 
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Figure S6A-D: CEP701 has Aurora kinase inhibitory activity. 
A, γ2A-FRT-TI-Jak2V617F/STAT3-YFP cells were treated with the indicated inhibitors for 24 
hrs. Subsequently, the cells were stained with the DNA dye Hoechst 33342 at a concentration of 
1 μg/ml for 20 min. Confocal imaging pictures show the changes of nuclear appearance. B, 2C4, 
HCT-116, and K-562 cells were treated with 500 nM of VX680 or CEP701 or left untreated for 
48 hrs. Subsequently, the nuclei were stained with Hoechst 33342 at a concentration of 1 μg/ml 
for 20 min. C, HEL cells were treated with 500 nM CEP701, VX680, TG101209 or 100 nM 
AT9283 for 24 or 48 hrs and then subjected to cell cycle analysis. The histograms demonstrate 
the emergence of an 8n peak after 24 hrs of treatment with AT9283 and VX680 and after 48 hrs 
of CEP701 treatment. Cell cycle profiles of TG101209 treated cells are shown as negative 
control. The results of one representative technical replicate of three biological replicates are 
shown. D, HEL cells were treated with 600 nM CEP701, TG101209, VX680 or 100 nM AT9283 
or left untreated for 24, 48 or 72 hrs. The mean values of the cell volume with standard deviations 
from 3 biological triplicates are shown.  
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Figure S6E-F: CEP701 has Aurora kinase inhibitory activity. 
E, UKE-1 (left panel) and BA/F3-EpoR-Jak2V617F (right panel) cells were treated with 100 
ng/ml of Nocodazole for 16 hrs to block the cells in the M phase of the cell cycle. Subsequently, 
the cells were incubated with different concentrations (0.25, 0.5 or 1 μM) of VX680 and CEP701 
or left untreated for 3 hrs. Quantitative Western blot detection was performed as described in 
Materials and Methods. The blots were detected with antibodies against phosphorylated histone 
H3 (P-H3) and histone H3 (H3). The bar diagrams below the Western blot representation show 
the quantitation of phospho-histone H3 signals relative to histone H3 expression for three 
biological replicates. F, IC50 values for Aurora A and B inhibition were determined in an in vitro 
kinase assay for the indicated inhibitors. The assays were performed by Caliper Discovery 
Alliances & Services “CDAS” applying the LabChip technology from Caliper Life Sciences 
using standard conditions and Staurosporine as a reference compound. IC50 values were 
determined using GraphPad Prism 5.01, log [inhibitor] vs. response-Variable slope 4PL curve fit 
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Figure S7: Aurora kinase inhibition rather suppresses growth of myeloid colonies. 
CD34+ cells of Jak2V617F-positive MPN patients were subjected to CFC assays in the presence 
of indicated Aurora kinase inhibitors at different concentrations. The amount of erythroid 
colonies (black bars) or myeloid colonies (white bars) grown from inhibitor-treated cells was 
calculated as percentage of maximum number of colonies in the untreated control. 
 
Figure S8: Jak and Aurora kinase inhibitors cooperate to suppress growth of Jak2V617F- 
expressing cells. 
CD34+ cells of Jak2V617F-positive MPN patients were subjected to CFC assays using the 
Aurora kinase inhibitor VX680 and the Jak2 inhibitor TG101348 in combination. The amount of 
erythroid colonies (black bars) or myeloid colonies (white bars) grown from inhibitor-treated 
cells was calculated as percentage of maximum number of colonies in the untreated control. 
 
Figure S9: Chou-Talalay analysis TG101209 and VX680 synergistically inhibit proliferation of 
BA/F3-EpoR-Jak2V617F cells  
BA/F3-EpoR-Jak2V617F cells were incubated with TG101209, VX680 or a combination thereof 
(ratio of concentrations was kept constant at 3:1). A dose-effect analysis of the drug combination 
was performed using the CompuSyn software. CI values were lower than 1 for all concentrations 
indicating a synergistic effect of the drug combination. 
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